论文部分内容阅读
目的探讨帕罗西汀联合莫沙必利和乳果糖治疗便秘型肠易激综合征的疗效。方法 76例便秘型肠易激综合征(IBS-C)患者随机分为两组:A组39例,联合采用口服帕罗西汀、莫沙必利和乳果糖治疗;B组37例,仅采用莫沙必利和乳果糖治疗。帕罗西汀20mg,每日晨口服;莫沙必利10mg和乳果糖10ml,每日口服3次。疗程4周,比较两组疗效和不良反应。结果 A组便秘症状改善较B组更为明显(P<0.05)。A组总有效率和伴随症状的改善率分别为92.3%和94.9%,高于B组的73.0%和70.3%(P<0.05)。两组不良反应相仿(P>0.05)。结论与口服莫沙必利和乳果糖比较,加用帕罗西汀口服治疗IBS-C疗效更好。
Objective To investigate the efficacy of paroxetine combined with mosapride and lactulose in the treatment of constipation-induced irritable bowel syndrome. Methods A total of 76 patients with constipation-induced irritable bowel syndrome (IBS-C) were randomly divided into two groups: group A, 39 patients were treated with oral paroxetine, mosapride and lactulose; group B, 37 patients, Will and lactulose treatment. Paroxetine 20mg, daily morning oral; mosapride 10mg and lactulose 10ml, 3 times daily oral. Treatment for 4 weeks, the two groups were compared efficacy and adverse reactions. Results The improvement of constipation in group A was more obvious than that in group B (P <0.05). The improvement rates of total effective rate and attending symptoms in group A were 92.3% and 94.9% respectively, which were higher than 73.0% and 70.3% in group B (P <0.05). Adverse reactions in both groups were similar (P> 0.05). Conclusion Compared with oral mosapride and lactulose, oral treatment with paroxetine IBS-C better.